*** Need an answer to your GCP query ? Post your query at HelpDesk ***
Follow us on




New Chemical Entity (NCE)

A drug that contains no active moiety that has been approved by the FDA in any other application submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act. An NCE is a molecule developed by the innovator company in the early drug discovery stage, which after undergoing clinical trials could translate into a drug that could be a cure for some disease. Synthesis of an NCE is the first step in the process of drug development.

Legislations, Regulations and Guidelines

This list of Legislations, Regulations and Guidelines govern human subjects research and clinical research as well as standards from international and regional organizations. This is useful for IRBs/IECs, Clinical Research Professionals and others who are involved in international research in order to familiarize with the applicable laws, regulations, and guidelines. This information includes General (applicable to most or all types of human subjects research), Drugs, Privacy/Data Protection related legislations, regulations and guidelines but excluded Human Biological Materials, Genetic, Embryos, Stem Cells, and Cloning Research. It may be necessary to review all standards to obtain a full understanding of the country’s requirements.

 

Definitions
Legislation – includes statutes, statutory instruments, legislative decrees, and constitutional provisions, if any, that relate to clinical research.
Regulations – refer to instruments that are created and issued under the name of governmental administrative bodies.
Guidelines – refer to non-binding instruments.

 

Disclaimer
This legal information does not constitute legal advice or opinions as to the current operative laws, regulations, or guidelines of any jurisdiction. And new standards are issued on a continuing basis, this information is not an exhaustive source of all current applicable laws, regulations, and guidelines relating to clinical research. Researchers and other individuals should check with drug regulatory authorities or other relevant bodies before starting research activities.

 

Reproduced with thanks: Respective country  specific regulatory websites , information supplied by some regulatory officials and International Compilation of Human Subject Research Protections, 2009 Edition, Office for Human Research Protections, U.S. Department of Health and Human Services

 

Argentina
Armenia
Australia
Austria
Bangladesh
Belgium
Bolivia
Bosnia
Botswana
Brazil
Bulgaria
Burma (Myanmar)
Canada
Chile
China, People's Republic of
Colombia
Confederation of Independent States
Costa Rica
Croatia
Cyprus
Czech Republic
Denmark
Egypt
Estonia
Ethiopia
 
«StartPrev1234NextEnd»
Page 1 of 4
 

Opinion Poll

What do you think, which of following is the major factor at site likely to impact data Quality?
 
This opinion poll provides an informal way for the clinical research community to express its views on current topics. The results are not a scientific poll and do not necessarily reflect the percentages of all clinical researchers who agree with these positions.

Links